Efficacy and safety of <scp>SDT</scp>‐001, a dual‐task digital device, in managing attention‐deficit/hyperactivity disorder symptoms in children and adolescents: a phase 3, randomized, standard treatment‐controlled study
SDT-001 demonstrated superior efficacy at week 6 in ADHD-RS-IV compared to TAU, and reductions in scores were maintained up to the following 12 weeks, indicating its potential as a novel digital therapeutic option for ADHD management.
Authors
- Nobuo Kawazoe (ORCID: https://orcid.org/0000-0002-5685-2005)
- Yoshihisa Kinoshita (ORCID: https://orcid.org/0000-0002-3138-5287)
- Takashi Okada (ORCID: https://orcid.org/0000-0001-5580-9913)
- Katsunaka Mikami (ORCID: https://orcid.org/0000-0002-8818-4945)
- Ryo Nishino (ORCID: https://orcid.org/0009-0002-3652-0211)
- Tasuku Miyajima
- Hiroki Fukuju (ORCID: https://orcid.org/0009-0001-8990-8175)
Institutions
- Tokai University (JP)
- Tokyo Kasei University (JP)
- Shionogi (Japan) (JP)
- Kyoto University Hospital (JP)
- Nara Medical University (JP)
Publication Details
- Journal
- Psychiatry and Clinical Neurosciences
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1111/pcn.13833
- Citations
- 2
- Primary Topic
- Attention Deficit Hyperactivity Disorder
- Type
- article
- Field-Weighted Citation Impact
- 2.94
Funders
- Shionogi